Effect of valerian on cognitive disorders and electroencephalography in hemodialysis patients: a randomized, cross over, double-blind clinical trial

Table 3 Mean difference of cognitive scores before and after intervention in each treatment periods in the groups

Index	group	First Period			Second Period
Index	group	N	Mean	SD	N	Mean	SD
Orientation	A^a	19	0.26	0.56	17	0.00	0.00
Orientation	B	20	0.10	0.31	20	0.25	0.72
	P-value	0.550			0.442
Immediate memory	A^a	19	0.05	0.23	17	0.00	0.00
Immediate memory	B	20	0.10	0.31	20	0.05	0.22
	P-value	0.813			0.798
Concentration and calculation	A^a	19	0.47	0.70	17	0.00	0.50
Concentration and calculation	B	20	0.00	0.32	20	0.30	0.47
	P-value	0.057			0.177
Remembrance	A^a	19	0.32	0.48	17	0.06	0.24
Remembrance	B	20	0.00	0.32	20	0.20	0.41
	P-value	0.113			0.478
Language and understanding	A^a	19	0.21	0.53	17	0.06	0.43
Language and understanding	B	20	0.15	0.37	20	0.15	0.37
	P-value	0.728			0.684
Space situation	A^a	19	0.00	0.00	17	0.00	0.00
Space situation	B	20	0.00	0.00	20	0.05	0.22
	P-value	1.00			0.798
Cognitive impairment (general)	A^a	19	1.32	1.38	17	0.12	0.78
	B	20	0.35	0.81	20	1.00	1.17
	P-value	0.028			0.030

^aThe group A took valerian capsules in the first therapeutic period of one month and placebo in the second therapeutic period of one month, and vice versa in group B

ISSN: 1471-2369